title: Microglial Ca(2+)-activated K(+) channels are possible molecular targets for the analgesic effects of S-ketamine on neuropathic pain.
abstract: Ketamine is an important analgesia clinically used for both acute and chronic pain. The acute analgesic effects of ketamine are generally believed to be mediated by the inhibition of NMDA receptors in nociceptive neurons. However, the inhibition of neuronal NMDA receptors cannot fully account for its potent analgesic effects on chronic pain because there is a significant discrepancy between their potencies. The possible effect of ketamine on spinal microglia was first examined because hyperactivation of spinal microglia after nerve injury contributes to neuropathic pain. Optically pure S-ketamine preferentially suppressed the nerve injury-induced development of tactile allodynia and hyperactivation of spinal microglia. S-Ketamine also preferentially inhibited hyperactivation of cultured microglia after treatment with lipopolysaccharide, ATP, or lysophosphatidic acid. We next focused our attention on the Ca(2+)-activated K(+) (K(Ca)) currents in microglia, which are known to induce their hyperactivation and migration. S-Ketamine suppressed both nerve injury-induced large-conductance K(Ca) (BK) currents and 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one (NS1619)-induced BK currents in spinal microglia. Furthermore, the intrathecal administration of charybdotoxin, a K(Ca) channel blocker, significantly inhibited the nerve injury-induced tactile allodynia, the expression of P2X(4) receptors, and the synthesis of brain-derived neurotrophic factor in spinal microglia. In contrast, NS1619-induced tactile allodynia was completely inhibited by S-ketamine. These observations strongly suggest that S-ketamine preferentially suppresses the nerve injury-induced hyperactivation and migration of spinal microglia through the blockade of BK channels. Therefore, the preferential inhibition of microglial BK channels in addition to neuronal NMDA receptors may account for the preferential and potent analgesic effects of S-ketamine on neuropathic pain.
authors: Department of Aging Science and Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
authors: Yoshinori
authors: Y
authors: Hayashi
authors: Kodai
authors: K
authors: Kawaji
authors: Li
authors: L
authors: Sun
authors: Xinwen
authors: X
authors: Zhang
authors: Kiyoshi
authors: K
authors: Koyano
authors: Takeshi
authors: T
authors: Yokoyama
authors: Shinichi
authors: S
authors: Kohsaka
authors: Kazuhide
authors: K
authors: Inoue
authors: Hiroshi
authors: H
authors: Nakanishi
mesh_terms: D000698:Analgesia / Q000379:methods; D000700:Analgesics / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D002478:Cells, Cultured; D006930:Hyperalgesia / Q000188:drug therapy / Q000378:metabolism; D007649:Ketamine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism; D009437:Neuralgia / Q000188:drug therapy* / Q000378:metabolism; D024681:Potassium Channels, Calcium-Activated / Q000378:metabolism*; D013127:Spinal Nerves / Q000187:drug effects / Q000293:injuries / Q000378:metabolism
chemical_list: D000700:Analgesics; D024681:Potassium Channels, Calcium-Activated; D007649:Ketamine